In total, 610 patients were randomized to receive degarelix (administered via subcutaneous injection) at a starting dose of 240 mg, followed by maintenance doses of 80 mg/month (n = 207 ...

Based on the data from this trial, the EMEA and FDA recently licensed degarelix 240/80 mg for the treatment of patients with advanced (hormone-sensitive) prostate cancer. Degarelix therefore ...